Back

Psychological Medicine

52 training papers 2019-06-25 – 2026-03-07

Top medRxiv preprints most likely to be published in this journal, ranked by match strength.

1
Neurocognitive deficits, psychotrauma, and inflammation shape major depressive disorder and its phenome features
2026-02-12 psychiatry and clinical psychology 10.64898/2026.02.11.26346056
Top 0.1% (11.7%)
Show abstract

BackgroundMajor depressive disorder (MDD) involves immune-metabolic dysregulation, psychosocial adversity, and multidomain cognitive disturbances, yet single cognitive indices often show small and inconsistent effects. We derived a multivariate Cambridge Neuropsychological Test Automated Battery (CANTAB)-based cognitive phenotype ("cognitype") and tested whether it adds explanatory value beyond adverse childhood experiences (ACEs) and an acute-phase protein (APP) index in acute-phase MDD. Metho...

2
GAMBIT: A Digital Tool to Train Distinct Inhibitory Control Mechanisms
2026-03-06 psychiatry and clinical psychology 10.64898/2026.03.05.26347639
Top 0.2% (11.1%)
Show abstract

Deficits in inhibitory control are common across a wide range of psychiatric disorders and are closely linked to symptom severity, including emotional dysregulation, anxiety, substance misuse, and self-harm, making them an appealing target for intervention. Cognitive training offers a low-cost, scalable, and non-invasive strategy to strengthen inhibitory control; however, most existing paradigms target only a single facet of inhibition and rarely account for environmental influences, such as aff...

3
Genetic evidence for repurposing immunomodulatory drugs for major depressive disorder
2026-02-09 psychiatry and clinical psychology 10.64898/2026.02.07.26345798
Top 0.2% (10.8%)
Show abstract

ObjectiveTo identify immunomodulatory drug targets with genetic evidence in major depressive disorder (MDD), probe symptom-level heterogeneity in their effects, and identify drug repurposing opportunities. MethodsWe used cis-Mendelian randomisation to evaluate the targets of 204 immunomodulatory compounds, including immunosuppressants, cytokine inhibitors, and anti-infectives. As exposures, we selected genetic instruments from nine genome-wide association studies (GWASs) of protein or gene tran...

4
Noninvasive brain stimulation combined with evidence-based psychotherapy for psychiatric disorders: A meta-analysis of optimal implementation parameters
2026-02-24 psychiatry and clinical psychology 10.64898/2026.02.19.26346650
Top 0.3% (10.6%)
Show abstract

Evidence-based psychotherapies are first-line treatments for psychiatric disorders, yet response rates remain suboptimal. Noninvasive brain stimulation (NIBS) may augment psychotherapy by modulating treatment-engaged circuits. We conducted a systematic review and meta-analysis of randomized controlled trials comparing active NIBS plus evidence-based psychotherapy versus sham NIBS plus psychotherapy. Following Cochrane methods, we searched six databases through February 2025, screening 1,017 reco...

5
Identifying an oculomotor phenotype for adolescent depression with an interleaved pro- and anti-saccade task
2026-02-24 psychiatry and clinical psychology 10.64898/2026.02.20.26346728
Top 0.3% (9.3%)
Show abstract

Numerous studies have shown that adults with depression have distinct oculomotor alterations during saccade tasks, but whether similar alterations occur in adolescents is largely unknown. The purpose of this study was to test if eye-tracking during a structured saccade task could distinguish a group of adolescents with depression from healthy controls. We hypothesized that, due to overlapping circuitry between depression pathology and the oculomotor system, adolescents with depression would show...

6
Clinical and genetic correlates of a circadian subtype of depression in the Australian Genetics of Depression Study
2026-02-25 psychiatry and clinical psychology 10.64898/2026.02.23.26346917
Top 0.4% (8.8%)
Show abstract

BackgroundWhile commonly accepted depressive subtypes reflect phenotypic differences, there has been minimal progress in identifying discrete pathophysiological pathways, biomarkers or differential therapeutic approaches which effectively guide clinical management. AimsTo test the biological validity and clinical utility of a circadian subtype of depression on the basis of clinical course, differential medication response (self-reported) and genetic risk profile. MethodsCross-sectional data we...

7
Direct and Indirect Genetic Effects of Parental Liabilities to Mental Health Conditions and Related Traits on Children's Behavioural Difficulties: A Multi-Cohort Study
2026-02-12 psychiatry and clinical psychology 10.64898/2026.02.10.26345985
Top 0.5% (8.7%)
Show abstract

BackgroundParental genetics matters for childrens behavioural difficulties, but the extent to which this is due to direct genetic transmission versus environmentally mediated indirect genetic effects remains unclear. MethodsWe studied eight European birth cohorts with over 33,000 family-based trio samples. We analysed polygenic scores (PGSs) for 13 mental health and neurodevelopmental conditions and their composite indices (PC1 and mean) representing general neuropsychiatric liabilities, as wel...

8
Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
2026-02-09 genetic and genomic medicine 10.64898/2026.02.06.26345742
Top 0.5% (8.5%)
Show abstract

Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to "any anxiety diagnosis". Additional genome-wide evidence to discern genetic differences between fear ...

9
Longer Sleep Duration Predicts Progression to Bipolar or Psychotic Disorders in Youth accessing Early Intervention Mental Health Services
2026-03-05 psychiatry and clinical psychology 10.64898/2026.03.04.26347669
Top 0.6% (8.5%)
Show abstract

BackgroundWhile growing evidence implicates sleep-wake and circadian rhythm disturbances (SCRDs) in the onset and course of mood and psychotic disorders, longitudinal studies using objective measures are limited. This clinical cohort study examined whether actigraphy-derived SCRDs (sleep duration, timing, and efficiency) predicted transition to (i) any full-threshold mental disorders; and then specifically: (ii) full-threshold bipolar or psychotic disorders or (iii) other full-threshold (i.e. de...

10
Genetic Signal Augmentation of Childhood-Onset and Treatment-Resistant Major Depression Reveals Distinct Biological Disorders
2026-03-03 psychiatry and clinical psychology 10.64898/2026.03.02.26347449
Top 0.7% (8.0%)
Show abstract

Major depression (MD) is a disorder class that exhibits substantial phenotypic and clinical heterogeneity, yet many large-scale molecular genetic investigations treat MD as a unitary outcome. Here, we applied Genomic Structural Equation Modeling (Genomic SEM) to characterize the genetic variation in two clinically relevant MD subtypes, childhood-onset (child-onset) and treatment-resistant MD, that are independent of the field-standard GWAS of MD in all its forms. In addition, we fit a complement...

11
Longterm Temporal Dynamics of Suicidal Ideation: A Dynamic Time Warping Analysis of Depression, Anxiety, Worry, and Mastery
2026-02-28 psychiatry and clinical psychology 10.64898/2026.02.20.26345909
Top 0.7% (8.0%)
Show abstract

BackgroundSuicidal ideation (SI) fluctuates over time, yet traditional static risk factors poorly align with its dynamics over time. Understanding dynamic symptom patterns may advance knowledge of the temporal interplay between SI and co-occurring symptoms in adults with depressive and anxiety disorders. Materials and methodsWe analyzed six waves (at baseline, and after 2, 4, 6, 9, and 13 years of follow-up) of the Netherlands Study of Depression and Anxiety (NESDA; n = 305, mean age 40.8 years...

12
Validation and Extension of a Risk Calculator to Predict Mood Recurrence in Young People with Bipolar Disorder
2026-03-02 psychiatry and clinical psychology 10.64898/2026.02.20.26346717
Top 0.7% (7.8%)
Show abstract

ObjectiveGiven the episodic nature of bipolar disorder (BD) and the variability in mood episode recurrence across individuals, accurate recurrence prediction is critical. The original COBY recurrence risk calculator (RC) was developed in a longitudinal youth cohort to estimate threshold recurrence risk. However, its accuracy for predicting subthreshold recurrences had not been fully evaluated. The objective of this study was to extend the previously developed COBY mood recurrence RC to predict b...

13
Plasma Lipid Alterations Track Multidimensional Psychosis Severity Across Diagnostic Boundaries
2026-02-26 psychiatry and clinical psychology 10.64898/2026.02.24.26346956
Top 0.7% (7.8%)
Show abstract

BackgroundLipidomic alterations have been reported across schizophrenia (SCZ) and bipolar disorder (BD), but findings are heterogeneous and often overlap across diagnoses, limiting diagnostic specificity. Associations between lipid profiles and illness severity have also been inconsistent when assessed using single symptom scales, raising the possibility that unidimensional measures fail to capture biologically relevant variation. Whether plasma lipidomic alterations relate to multidimensional p...

14
Lithium treatment after electroconvulsive therapy in bipolar disorder: A nationwide target trial emulation
2026-02-14 psychiatry and clinical psychology 10.64898/2026.02.11.26346116
Top 0.7% (7.8%)
Show abstract

ObjectivesElectroconvulsive Therapy (ECT) is an effective treatment for bipolar disorder, particularly in severe acute cases or for illness resistant to pharmacotherapy. However, the risk of relapse following ECT is high, necessitating intervention to reduce this risk. Based on findings from ECT studies in unipolar depression and its well-known mood-stabilizing properties, it is likely that lithium treatment may reduce the risk of relapse of bipolar disorder following ECT. Therefore, we conduct...

15
Data-driven profiles of psychosis stages reveal distinct and overlapping clinical, cognitive, and neuroanatomical phenotypes
2026-03-05 psychiatry and clinical psychology 10.64898/2026.03.04.26347618
Top 0.8% (7.7%)
Show abstract

Psychotic disorders are increasingly recognized as the extreme end of a progressive psychopathology continuum, with less advanced stages including the asymptomatic familial high-risk state (FHR), the help-seeking clinical high-risk state (CHR), and first episode psychosis (FEP). However, we lack a comprehensive study of clinical, cognitive, functional, and neuroanatomical markers across all three early stages of psychosis, limiting our understanding of how the multimodal phenotypes which define ...

16
IL-17A, IFN-γ, and MIP-3α Plasma Profiles Predict Clinical Stage Transition in First-Episode Psychosis
2026-02-22 psychiatry and clinical psychology 10.64898/2026.02.17.26346145
Top 0.8% (7.6%)
Show abstract

BackgroundEarly detection of individuals at risk for clinical deterioration in first-episode psychosis (FEP) remains a vital challenge in psychiatric care. Emerging evidence indicates that immune dysregulation might play a crucial role in the pathophysiology and progression of psychotic disorders. AimsThis study examined the predictive potential of a plasma cytokine and chemokine panel in anticipating clinical stage transition of FEP patients. MethodUsing multiplex immunoassays, plasma samples...

17
Reproducible symptom subtypes of depression identified using unsupervised machine learning
2026-02-16 psychiatry and clinical psychology 10.64898/2026.02.13.26346271
Top 0.8% (7.6%)
Show abstract

Depression is a heterogeneous disorder, often diagnosed based on symptom co-occurrence. However, individuals may present with markedly different symptom profiles, potentially reflecting distinct underlying mechanisms. Identifying common patterns of symptoms using data-driven approaches could help clarify the heterogeneity of depression. Furthermore, examining the sociodemographic and lifestyle characteristics, health status, and polygenic scores of individuals with specific symptom profiles may ...

18
Psilocybin services and mental health outcomes within Oregon's state-regulated model
2026-02-19 psychiatry and clinical psychology 10.64898/2026.02.18.26346580
Top 0.8% (7.6%)
Show abstract

BackgroundIn 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using naturally-derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context. AimsTo evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days post-psilocybin session under the Oregon state-regulated model , and document session-related adverse events and doses consum...

19
Diagnostic Accuracy and Clinical Reasoning of Multiple Large Language Models in Psychiatry
2026-02-09 psychiatry and clinical psychology 10.64898/2026.02.03.26345402
Top 0.9% (7.5%)
Show abstract

ImportanceLarge language models (LLMs) have demonstrated diagnostic potential in several medical specialties, but their application to psychiatry - where diagnosis relies heavily on clinical judgment, narrative interpretation, and reasoning under uncertainty - remains insufficiently evaluated. ObjectiveTo evaluate diagnostic accuracy and clinician-judged reasoning quality of multiple large language models using psychiatric case vignettes. DesignMixed-methods evaluation study of diagnostic accu...

20
Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
2026-03-06 psychiatry and clinical psychology 10.64898/2026.03.05.26347694
Top 1.0% (7.4%)
Show abstract

Background At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population. Methods CHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences. Results The sample comprised 55 CHR-P individuals (24.3 years and 69% female). Mo...